About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

FDA Allays Pradaxa Concerns

by Kathy Jones on November 3, 2012 at 5:14 PM
Font : A-A+

 FDA Allays Pradaxa Concerns

The US Food and Drug Administration declared that the risk of bleeding in patients who are new to Boehringer Ingelheim's blood-clot preventer Pradaxa is not higher than the currently used blood thinner warfarin.

The FDA had earlier approved Ingelheim's Pradaxa for preventing strokes in patients who suffer from atrial fibrillation but safety concerns over the pill emerged following reports that it posed a risk for bleeding in patients who were newly introduced to the drug.

Advertisement

The FDA hopes that this announcement will allay any safety concerns over the pill.

The FDA compared the insurance claims and electronic health data of both warfarin and Pradaxa users from October 2010 to December 2011 and found that instances of intracranial and gastrointestinal hemorrhage in patients taking warfarin was 1.8 to 2.6 times higher compared to Pradaxa. "The results indicate that the observed bleeding rates associated with new use of Pradaxa do not appear to be higher than the bleeding rates associated with new use of warfarin", he FDA said.


Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Vent Forte (Theophylline) Accident and Trauma Care Daily Calorie Requirements Noscaphene (Noscapine) Blood - Sugar Chart Post-Nasal Drip Turmeric Powder - Health Benefits, Uses & Side Effects Sanatogen The Essence of Yoga Indian Medical Journals
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use